Safety and Efficacy of Buprenorphine/Naloxone in Opioid-Dependent Patients
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Opioid dependence is a growing problem. Methadone is an established agent for the treatment of opioid dependence, but there is a risk of this agent being abused, a potential for interaction with antiretroviral agents and a risk of cardiac toxicity. Another option is the partial μ-opioid receptor opioid agonist buprenorphine, which has been used successfully to manage opioid dependence. While the risk of abuse is lower than that for methadone, there is still a risk. The sublingual combination formulation of buprenorphine and the opioid receptor antagonist naloxone (buprenorphine/naxolone) is a newer agent with reduced abuse potential, and has been shown to have promising efficacy for opioid dependence.
Objectives: We describe the results of an observational study investigating the safety and efficacy of buprenorphine/naloxone in opioid-dependent patients.
Methods: A total of 77 patients were included and were switched from buprenorphine to sublingual tables of buprenorphine/naloxone; the buprenorphine dosage was titrated to achieve good control of withdrawal symptoms. The prevalence of withdrawal symptoms, craving, constipation, cramps, insomnia, sexual activity, depression, sweating, distress, bone/joint pain and drowsiness were compared over the first 30 days of treatment (period 1) and the total 120-day study duration (period 2).
Results: The average buprenorphine/naloxone dose in period 1 was 7.3 mg/day and 12.7 mg/day in period 2. Most patients did not experience any withdrawal symptoms in either period 1 or period 2. Fewer than 20% of patients experienced any cravings over the 120-day study period. Importantly, the adverse effects observed were usually mild, with very few patients experiencing significant adverse effects.
Conclusions: This study shows that buprenorphine/naloxone is an effective and well tolerated treatment for opioid withdrawal when the dosage is titrated to achieve good control of withdrawal symptoms. Switching from buprenorphine alone to buprenorphine/naloxone was possible with very little discomfort for the patient and effective retained patients in treatment.
- US Department of Health and Human Services. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: a treatment improvement protocol TIP 40. 2004
- National Institute on Drug Abuse. Principles of drug addiction treatment: a research based guide. Evidence-based approaches to drug addiction treatment. [cited 2009 21 Oct]; Available from: http://www.drugabuse.gov/PODAT/ Evidence.html#Pharm
- Goldman FR, Thistel CI. Diversion of methadone: illicit methadone use among applicants to two metropolitan drug abuse programs. Int J Addict 1978 Aug; 13(6): 855–62
- Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003 (2): CD002207
- Prescribing Information — Methadone (Italy). [cited 2009 14 Nov]; Available from: http://www.pharmamarketing.it/ cont/020ser/050pro/default.asp?method=Mostra_Contenuto &id_cont=61641
- Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007 Dec 10; 167(22): 2469–75 CrossRef
- Best SE, Oliveto AH, Kosten TR. Opioid addiction: recent advances in detoxification and maintenance therapy. CNS Drugs 1996; 6(4): 301–14 CrossRef
- Chapleo CB, Walter DS. The buprenorphine-naloxone combination product. Res Clin Forums 1997; 19(2): 55–8
- Law FD, Myles JS, Daglish MRC. The clinical use of buprenorphine in opiate addiction: evidence and practice. Acta Neuropsychiatria 2004; 16: 246–74 CrossRef
- Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend 2003 May21;70(2Suppl.): S29–37 CrossRef
- Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 2003 May 21; 70(2 Suppl.): S59–77 CrossRef
- Bickel WK, Stitzer ML, Bigelow GE, et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988 Oct; 247(1): 47–53
- Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007 Apr 17; 88(1): 75–8 CrossRef
- Bell J, Byron G, Gibson A, et al. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Drug Alcohol Rev 2004 Sep;23(3): 311–7 CrossRef
- European Medicines Agency. Scientific discussion (Suboxone) [online]. [cited 2007 21 Oct]; Available from: http://www. emea.europa.eu/humandocs/PDFs/EPAR/suboxone/069706 en6.pdf
- Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs 2006; 20(9): 697–712 CrossRef
- Harris DS, Jones RT, Welm S, et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000 Dec 22; 61(1): 85–94 CrossRef
- Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003 Sep 4; 349(10): 949–58 CrossRef
- Kamien JB, Branstetter SA, Amass LA. Buprenorphinenaloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid dependent patients. Heroin Addict Relat Clin Probl 2008; 10(4): 5–18
- Kakko J, Gronbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007 May; 164(5): 797–803 CrossRef
- Reckitt Benckiser Pharmaceuticals Inc. Suboxone (buprenorphine HCl and naloxone HCl dihydrate sublingual tablets)/Subutex (buprenorphine HCl sublingual tablets): US prescribing information [online]. [cited 2009 16 November]; Available from: http://http://www.suboxone.com/patients/pi
- Healy R. Effectiveness of two opioid antagonists in treating opioid-induced constipation. Br J Nurs 2009 Sep 10–23; 18(16): 998–1002
- Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 2008 Nov 5; 300(17): 2003–11 CrossRef
- Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005 Aug; 100(8): 1090–100 CrossRef
- Safety and Efficacy of Buprenorphine/Naloxone in Opioid-Dependent Patients
Clinical Drug Investigation
Volume 30, Issue 1 Supplement, pp 21-26
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors